A 61-year-old woman presented with progressive hoarseness (voice handicap index-10 [VHI-10] = 25) and rhinorrhea over a 3-week period after an upper respiratory infection. Despite treatment with oral corticosteroids and antibiotics, she progressed to near-aphonia. Her medical history included a remote history of smoking, as well as rheumatoid arthritis (RA) and Hashimoto disease. Her RA was well controlled on the tumor necrosis factor-alpha (TNF-α) inhibitor certolizumab pegol and sulfasalazine.
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Flexible laryngoscopy with stroboscopy showed normal vocal fold motion with diffuse vocal fold erythema, edema, and a severely decreased mucosal wave ( figure  1 ). Reduced voice use and oral corticosteroids were begun. A rhinology consult revealed methicillin-sensitive Staphylococcus aureus and Pseudomonas aeruginosa on endoscopic culture. Sinus computed tomography showed minimal mucosal thickening in both bilateral maxillary and ethmoid sinuses with bilateral ostiomeatal obstruction.
Despite the oral culture, specific antibiotics, and nasal irrigations of budesonide, mupirocin, gentamicin, and saline for 12 weeks, the patient's rhinorrhea and dysphonia (VHI-10 = 32) worsened, and her follow-up laryngeal examination revealed severe bilateral erythema and edema of the vocal folds without any visible mucosal wave (figure 2).
Allergy skin testing, a chest x-ray, and an immunodeficiency workup-including quantitative immunoglobulin, complement T-cell subpopulations, mannose lectin binding levels, antineutrophil cytoplasmic antibody, and angiotensin-converting enzyme-were all within normal limits.
In consultation with the patient's rheumatologist, her certolizumab pegol was discontinued and replaced with LARYNGOSCOPIC CLINIC This patient's persistent suppurative laryngitis secondary to her suppurative chronic rhinosinusitis is attributable to the immunosuppression from the TNF-α inhibitor certolizumab pegol, and it resolved once that drug was discontinued.
1,2 A known side effect of the whole class of TNF-α inhibitors is increased susceptibility to fungal, bacterial, and viral infections. 3 The American College of Rheumatology recommends discontinuation of TNF-α inhibitors in patients with bacterial infections requiring antibiotic therapy or with severe upper respiratory infection. 4 Cessation of the TNF-α inhibitor, combined with continued antibiotic therapy, led to resolution of the patient's infectious rhinosinusitis and subsequently her related suppurative laryngitis. This clearly demonstrates the importance of following the recommendations of stopping a TNF-α inhibitor in patients with infection. It also demonstrates dramatically the causation of suppurative laryngitis from purulence draining from the nasal cavity. 
